Avandia Not Losing Market Share To Januvia, GSK Reports
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck’s DPP-4 inhibitor is largely taking business from metformin and sulfonylureas, GSK exec Stout asserts.
You may also be interested in...
Januvia Gets Fast Start; Uptake Seen In Variety Of Diabetes Settings, Merck Says
Company reports sales of $42 million for sitagliptin during the DPP-4 inhibitor's first quarter on the market.
GSK Adopting New Marketing Push For Avandia
ADOPT trial results, which show rosiglitazone beats metformin for maintaining glycemic control, could double the market for the insulin sensitizer.
Avandamet Supply Issues Are Resolved, Allowing Launch Of New Indication
GlaxoSmithKline's announcement about renewed Avandamet availability follows the approval of the type 2 diabetes drug for first-line use.